Contineum Therapeutics Q3 EPS $(3.55), Cash Position $117.9M
Portfolio Pulse from Benzinga Newsdesk
Contineum Therapeutics reported a Q3 EPS of $(3.55) and a cash position of $117.9 million.
May 16, 2024 | 8:26 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Contineum Therapeutics reported a Q3 EPS of $(3.55), which is a significant loss. However, the company maintains a strong cash position of $117.9 million.
The significant loss per share is likely to negatively impact investor sentiment in the short term, despite the strong cash position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100